| P50 | author | Elda Righi | Q79385925 |
| | Matteo Bassetti | Q88607142 |
| P2860 | cites work | Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa | Q24612271 |
| | Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America | Q29616084 |
| | Inactivation of CMY-2 beta-lactamase by tazobactam: initial mass spectroscopic characterization | Q31926664 |
| | Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein | Q33422951 |
| | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains | Q33613660 |
| | Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions | Q34045418 |
| | Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes | Q34164594 |
| | Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention | Q34190800 |
| | A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection | Q34582295 |
| | In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms | Q35666617 |
| | Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses | Q36018548 |
| | Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases | Q36357629 |
| | Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern | Q37091253 |
| | Clinical and economic burden of antimicrobial resistance. | Q37291374 |
| | New antibiotics for bad bugs: where are we? | Q38132217 |
| | In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae | Q39757874 |
| | Kinetic interactions of tazobactam with beta-lactamases from all major structural classes | Q39865634 |
| | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients | Q41839265 |
| | Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa | Q42430254 |
| | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa | Q42910111 |
| | Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae | Q42994553 |
| | Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model | Q43085417 |
| | Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. | Q46018796 |
| | Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance | Q46711065 |
| | In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals. | Q54391402 |
| P433 | issue | 2 | |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 151-160 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Future Microbiology | Q15759961 |
| P1476 | title | Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections | |
| P478 | volume | 10 | |